10/02/23 9:00 AMNasdaq : SAVA clinical trialhigh shortCassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s DiseaseCassava Sciences, Inc. (Nasdaq:RHEA-AIneutral
09/18/23 9:15 AMNasdaq : SAVA clinical trialhigh shortCassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s DiseaseAn Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials. The DSMB Recommended the Phase 3 Trials of Simufilam Continue as Planned, Without Modification AUSTIN, Texas, Sept. 18, 2023 (GLOBERHEA-AIneutral
09/11/23 9:10 AMNasdaq : SAVA high shortCassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s DiseaseNew cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease. Results corroborate prior research from other academic researchers. These data once again confirm the biological activity of simufilam. AUSTIN, Texas, Sept. 11, 2023 (GLOBERHEA-AIneutral
09/06/23 9:15 AMNasdaq : SAVA conferenceshigh shortCassava Sciences Invited to Present in Four Upcoming Investor ConferencesCassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the following investor conferences. Event: Morgan Stanley - 21 stRHEA-AIneutral
08/03/23 9:07 AMNasdaq : SAVA earningshigh shortCassava Sciences Reports Q2 2023 Financial Results and Operating UpdatesResults of a randomized, controlled trial of oral simufilam in Alzheimer’s disease announced July 2023. Over 1,587 patients now enrolled in Phase 3 studies of simufilam in Alzheimer’s disease, an increase of over 340 patients in the last three months. Completion of patient enrollment for Phase 3RHEA-AInegative
07/05/23 9:15 AMNasdaq : SAVA high shortOral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s DiseaseSimufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease. Drug Effects Favored Mild Alzheimer’s Disease. In Mild Alzheimer’s, Simufilam Improved Cognition Scores Over 6 Months. In Mild Alzheimer’s, Simufilam Stabilized CognitionRHEA-AIneutral
06/27/23 9:15 AMNasdaq : SAVA high shortNew Research Shows Simufilam Suppresses Overactive mTORCassava Sciences, Inc. (Nasdaq:RHEA-AIneutral
06/12/23 9:15 AMNasdaq : SAVA high shortNew Publication Highlights Basic Science Supporting SimufilamCassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stageRHEA-AIneutral
06/01/23 9:15 AMNasdaq : SAVA conferenceshigh shortCassava Sciences to Present at the Jefferies Global Healthcare ConferenceCassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City. When :RHEA-AIneutral
05/11/23 9:15 AMNasdaq : SAVA high shortCassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s DiseaseThe Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease. Primary Outcome Measures Are Safety and Change in Cognition Scores. Top-line Clinical Results of the CMS Are Expected in Q3 2023. AUSTIN, Texas, May 11, 2023RHEA-AIneutral